Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EBITDA (2018 - 2025)

X4 Pharmaceuticals' EBITDA history spans 8 years, with the latest figure at -$23.7 million for Q4 2025.

  • For Q4 2025, EBITDA rose 33.64% year-over-year to -$23.7 million; the TTM value through Dec 2025 reached -$86.9 million, down 138.68%, while the annual FY2025 figure was -$86.9 million, 131.98% down from the prior year.
  • EBITDA reached -$23.7 million in Q4 2025 per XFOR's latest filing, up from -$27.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $71.1 million in Q2 2024 to a low of -$37.3 million in Q1 2024.
  • Average EBITDA over 5 years is -$20.2 million, with a median of -$25.4 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 375.54% in 2024, then plummeted 136.89% in 2025.
  • A 5-year view of EBITDA shows it stood at -$29.1 million in 2021, then rose by 11.97% to -$25.6 million in 2022, then rose by 1.48% to -$25.2 million in 2023, then plummeted by 41.73% to -$35.7 million in 2024, then surged by 33.64% to -$23.7 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's EBITDA are -$23.7 million (Q4 2025), -$27.5 million (Q3 2025), and -$26.2 million (Q2 2025).